| First Author | Meyer DS | Year | 2014 |
| Journal | Oncogene | Volume | 33 |
| Issue | 3 | Pages | 398-402 |
| PubMed ID | 23318421 | Mgi Jnum | J:320390 |
| Mgi Id | MGI:6872064 | Doi | 10.1038/onc.2012.585 |
| Citation | Meyer DS, et al. (2014) Tyrosine phosphatase PTPalpha contributes to HER2-evoked breast tumor initiation and maintenance. Oncogene 33(3):398-402 |
| abstractText | Protein tyrosine phosphatase alpha (PTPalpha/PTPRA) was shown previously to be overexpressed in human primary breast cancers, and to suppress apoptosis in estrogen receptor-negative breast cancer cells in vitro. However, it is not known whether PTPalpha is important for mammary tumor initiation, maintenance and/or progression. We have used a combination of three-dimensional cultures, a transgenic mouse model of breast cancer lacking PTPalpha as well as xenografts of human breast cancer cell lines to address these questions. We found that PTPalpha knockdown after overt tumor development reduced the growth of HER2-positive human breast cancer cell lines, and that this effect was accompanied by a reduction in AKT phosphorylation. However, PTPalpha knockdown did not affect invasiveness of HER2-positive human breast cancer cells grown in three-dimensional cultures. Moreover, in MMTV-NeuNT/PTPalpha(-/-) mice, PTPalpha ablation did not affect NeuNT-evoked tumor onset or metastasis but decreased the number of tumors per mouse. Thus, we demonstrate that PTPalpha contributes to both HER2/Neu-mediated mammary tumor initiation and maintenance. Our results suggest that inhibition of PTPalpha can have a beneficial effect on HER2-positive breast cancers, but that inhibition of additional targets is needed to block breast tumorigenesis. |
